Management of the thalassemias

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 6, 2013, Pages

  Olivieri, Nancy F ^a   Brittenham, Gary M ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADENOHYPOPHYSIS; ARTICLE; BLOOD; BLOOD TRANSFUSION; ECONOMICS; HEART MUSCLE; HUMAN; IRON OVERLOAD; LIVER; METABOLISM; PANCREAS; THALASSEMIA;

BENZOATES; BLOOD TRANSFUSION; DEFEROXAMINE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MYOCARDIUM; PANCREAS; PITUITARY GLAND, ANTERIOR; PYRIDONES; THALASSEMIA; TRIAZOLES;

EID: 84878962035     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a011767     Document Type: Article

References (102)

1. Allen A., Fisher C, Premawardhena A, Peto T, Allen S, Arambepola M., Thayalsutha V, Olivieri N, Weatherall D. 2010. Adaptation to anemia in hemoglobin E-ss thalassemia. Blood 116: 5368-5370.
2. Anderson L.J., Holden S, Davis B, Prescott E, Charrier CC, Bunce N.H., Firmin DN, Wonke B, Porter J, Walker JM, et al. 2001. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis ofmyocardial iron overload. Eur Heart J 22: 2171-2179.
3. Anderson L.J., Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. 2002. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 360: 516-520.
4. Anderson L.J., Westwood MA, Prescott E, Walker JM, Pennell D.J., Wonke B. 2006. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 115: 106-108.
5. Angelucci E., Brittenham GM, McLaren CE, Ripalti M, Baronciani D., Giardini C, Galimberti M, Polchi P, Lucarelli G. 2000. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343: 327-331.
6. Angelucci E., Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J., Ripalti M, Sodani P, Tomassoni S, Visani G, et al. 2002. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100: 17-21.
7. Argyropoulou M.I., Kiortsis DN, Efremidis SC. 2003. MRI of the liver and the pituitary gland in patients with β-thalassemia major: Does hepatic siderosis predict pituitary iron deposition? Eur Radiol 13: 12-16.
8. Arora N., Daley GQ. 2012. Pluripotent stem cells in research and treatment of hemoglobinopathies. Cold Spring Harb Perpect Med 2: a011841.
9. AuWY, LamWW, ChuW, Tam S, Wong WK, Liang R, Ha SY. 2008a. AT2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematologica 93: 116-119.
10. Au W.Y., Lam WW, Chu WW, Yuen HL, Ling AS, Li RC, Chan H.M., Lee HK, Law MF, Liu HS, et al. 2008b. A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong. Haematologica 93: 784-786.
11. Barry M., Flynn DM, Letsky EA, Risdon RA. 1974. Longterm chelation therapy in thalassaemia major: Effect on liver iron concentration, liver histology, and clinical progress. Br Med J 2: 16-20.
12. Beau-Salinas F, Guitteny MA, Donadieu J, Jonville-Bera AP, Autret-Leca E. 2009. High doses of deferiprone may be associated with cerebellar syndrome. BMJ 338: a2319.
13. Bergeron C., Kovacs K. 1978. Pituitary siderosis. Ahistologic, immunocytologic, and ultrastructural study. Am J Pathol 93: 295-309.
14. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F., Gamberini MR, Sabato V, Melevendi C, Cappellini M.D., Verlato G. 1998. Survival and disease complications in thalassemia major. Ann NY Acad Sci 850: 227-231.
15. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini M.D., Del Vecchio GC, Romeo MA, Forni GL, Gamberini M.R., Ghilardi R, et al. 2004a. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
16. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P., Maggio A, Renda D, Lai ME, Mandas A, Forni G., et al. 2004b. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 124: 114-117.
17. BreuerW, Hershko C, Cabantchik ZI. 2000. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 23: 185-192.
18. Brittenham GM. 2011. Iron-chelating therapy for transfusional iron overload. N Engl J Med 364: 146-156.
19. Brittenham G.M., Farrell DE, Harris JW, Feldman ES, Danish E.H., Muir WA, Tripp JH, Bellon EM. 1982. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 307: 1671-1675.
20. Brittenham G.M., Cohen AR, McLaren CE, Martin MB, Griffith P.M., Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW. 1993. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42: 81-85.
21. Brittenham G.M., Griffith PM, Nienhuis AW, McLaren CE, Young N.S., Tucker EE, Allen CJ, Farrell DE, Harris JW. 1994. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331: 567-573.
22. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman M.H., Holland FJ. 1990. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 323: 713-719.
23. Callender S.T., Weatherall DJ. 1980. Iron chelation with oral desferrioxamine. Lancet 316: 689.
24. Cao A., Kan YW. 2013. The prevention of thalassemia. Cold Spring Harb Perpect Med 3: a011775.
25. Cappellini M.D., Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L., Aydinok Y, Kattamis A, Kilinc Y, Porter J, et al. 2006. A phase 3 study of deferasirox (ICL670), a oncedaily oral iron chelator, in patients with β-thalassemia. Blood 107: 3455-3462.
26. Cappellini M.D., Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M., Gattermann N, Giraudier S, Lee JW, Chan LL, et al. 2010. Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 95: 557-566.
27. Cartwright G.E., Edwards CQ, Kravitz K, Skolnick M, Amos D.B., Johnson A, Buskjaer L. 1979. Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med 301: 175-179.
28. Cazzola M., Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y., De Stefano P. 1997. A moderate transfusion regimen may reduce iron loading in β-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 37: 135-140.
29. Chan Y.L., Pang LM, Chik KW, Cheng JC, Li CK. 2002. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: Predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol 32: 492-497.
30. Chatterjee R., Katz M, Oatridge A, Bydder GM, Porter JB. 1998. Selective loss of anterior pituitary volume with severe pituitary-gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrest. Ann NY Acad Sci 850: 479-482.
31. Christoforidis A., Haritandi A, Perifanis V, Tsatra I, Athanassiou-Metaxa M., Dimitriadis AS. 2007. MRI for the determination of pituitary iron overload in children and young adults with β-thalassaemia major. Eur J Radiol 62: 138-142.
32. Cohen A.R., Galanello R, Piga A, De Sanctis V, Tricta F. 2003. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102: 1583-1587.
33. Cohen A.R., Glimm E, Porter JB. 2008. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 111: 583-587.
34. Davis B.A., Porter JB. 2000. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood 95: 1229-1236.
35. Davis B.A., O'Sullivan C, Jarritt PH, Porter JB. 2004. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104: 263-269.
36. Delea T.E., Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak P.D., Coates TD. 2007. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review. Transfusion 47: 1919-1929.
37. De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. 2006. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassemia. J Pediatr Endocrinol Metab 19: 471-480.
38. EuropeanMedicines Agency. 2009. Ferriprox (deferiprone): Summary of product characteristics. European Public Assessment Report, rev. ed. 14 (http://wwwemaeuropaeu/ humandocs/Humans/EPAR/ferriprox/ferriproxhtm).
39. Farmaki K., Tzoumari I, Pappa C, Chouliaras G, BerdoukasV. 2010. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 148: 466-475.
40. Food and Drug Administration. 2011. Briefing document for the Oncologic Drugs Advisory Committee Meeting, September 14 (http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ UCM271537.pdf).
41. Fujisawa I., Morikawa M, Nakano Y, Konishi J. 1988. Hemochromatosis of the pituitary gland: MR imaging. Radiology 168: 213-214.
42. Gabutti V., Piga A. 1996. Results of long-term iron-chelating therapy. Acta Haematol 95: 26-36.
43. Galanello R., Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. 2003. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 43: 565-572.
44. Gamberini M.R., De Sanctis V, Gilli G. 2008. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: Incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev 6: 158-169.
45. Garbowski M., Eleftheriou P, Pennell D Tanner M Porter JB. 2008. Impact of compliance, ferritin and LIC on longterm trends in myocardial T2* with deferasirox. Blood 112: 116.
46. Higgs DR. 2009. The pathophysiology and clinical features of a thalassemia. In Disorders of hemoglobin (ed. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ), pp. 266-295. Cambridge University Press, Cambridge.
47. Iancu T.C., Neustein HB. 1977. Ferritin in human liver cells of homozygous β-thalassaemia: Ultrastructural observations. Br J Haematol 37: 527-535.
48. Jacobs E.M., Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu D.Y., Jansen EH, Jauhiainen K, Sturm B, Porter JB, et al. 2005. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal Biochem 341: 241-250.
49. Jensen P.D., Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. 2003. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: Indication of close relation between myocardial iron content and chelatable iron pool. Blood 101: 4632-4639.
50. Kirk P., Roughton M, Porter JB, Walker JM, Tanner MA, Patel J., Wu D, Taylor J, Westwood MA, Anderson LJ, et al. 2009. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 120: 1961-1968.
51. Ko C., Siddaiah N, Berger J, Gish R, Brandhagen D, Sterling RK, Cotler SJ, Fontana RJ, McCashland TM, HanSH, et al. 2007. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: Results from the National Hemochromatosis Transplant Registry. Liver Int 27: 1394-1401.
52. Lucarelli G., Isgrò A, Sodani P, Gaziev J. 2012. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perpect Med 2: a011825.
53. Midiri M., Lo Casto A, Sparacia G, D'Angelo P, Malizia R, Finazzo M., Montalto G, Solbiati L, Lagalla R, De Maria M. 1999. MR imaging of pancreatic changes in patients with transfusion-dependent β-thalassemia major. AJR Am J Roentgenol 173: 187-192.
54. Modell B., Khan M, Darlison M. 2000. Survival in β-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 355: 2051-2052.
55. Modell B., Khan M, Darlison M, King A, Layton M, Old J, Petrou M., Varnavides L. 2001. A national register for surveillance of inherited disorders: β-Thalassaemia in the United Kingdom. BullWorld Health Org 79: 1006-1013
56. Musallam K.M., Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT. 2011. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 96: 1605-1612.
57. Nienhuis A.W., Persons DA. 2012. Development of gene therapy for thalassemia. Cold Spring Harb Perpect Med 2: a011833.
58. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld E.J., Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D., Sizer KC, et al. 2003. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361: 1597-1602.
59. Noetzli L.J., Carson SM, Nord AS, CoatesTD, Wood JC. 2008. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 112: 2973-2978.
60. Noetzli L.J., Papudesi J, Coates TD, Wood JC. 2009. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 114: 4021-4026.
61. Noetzli L.J., Mittelman SD, Watanabe RM, Coates TD, Wood JC. 2011a. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol doi: 10.1002/ ajh.22223.
62. Noetzli L.J., Panigrahy A, Mittelman SD, Hyderi A, Dongelyan A, Coates TD, Wood JC. 2011b. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol doi: 10.1002/ajh.22247.
63. Novartis Pharmaceuticals. 2010. Exjade (deferasirox) prescribing information (http://www.exjade.com).
64. Olivieri N.F., Brittenham GM. 1997. Iron-chelating therapy and the treatment of thalassemia. Blood 89: 739-761.
65. Olivieri N.F., Weatherall DJ. 2009. Clinical aspects of β thalassemia and related disorders. In Disorders of hemoglobin (ed. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ), pp. 357-416. Cambridge University Press, Cambridge.
66. Olivieri N.F., Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N., Logan W, Mitchell D, Ricci G, Skarf B, et al. 1986. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 314: 869-873.
67. Olivieri N.F., Koren G, Hermann C, Bentur Y, Chung D, Klein J., St Louis P, Freedman MH, McClelland RA, Templeton DM. 1990. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336: 1275-1279.
68. Olivieri N.F., Koren G, Harris J, Khattak S, Freedman MH, Templeton D.M., Bailey JD, Reilly BJ. 1992. Growth failure and bony changes induced by deferoxamine. AmJ Pediatr Hematol Oncol 14: 48-56.
69. Olivieri N.F., Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. 1994. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 331: 574-578.
70. Olivieri N.F., Brittenham GM, Matsui D, Berkovitch M, Blendis L.M., Cameron RG, McClelland RA, Liu PP, Templeton D.M., Koren G. 1995. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 332: 918-922.
71. Pennell D.J., Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A., Gotsis ED, Tanner MA, Smith GC, Westwood M.A., et al. 2006. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107: 3738-3744.
72. Piga A., Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A., Donato G, Bordone E, Lavagetto A, Zanaboni L, et al. 2006. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91: 873-880.
73. Pippard M.J., Weatherall DJ. 1984. Iron absorption in nontransfused iron loading anaemias: Prediction of risk for iron loading, and response to iron chelation treatment, in β thalassaemia intermedia and congenital sideroblastic anaemias. Haematologia (Budap) 17: 17-24.
74. Pippard M.J., Letsky EA, Callender ST, Weatherall DJ. 1978. Prevention of iron loading in transfusion-dependent thalassaemia. Lancet 1: 1178-1181.
75. Pippard M.J., Callender ST, Warner GT, Weatherall DJ. 1979. Iron absorption and loading in β-thalassaemia intermedia. Lancet 2: 819-821.
76. Pippard M.J., Callender ST, Finch CA. 1982. Ferrioxamine excretion in iron-loaded man. Blood 60: 288-294.
77. Porter JB. 2001. Practical management of iron overload. Br J Haematol 115: 239-252.
78. Porter JB. 2007. Concepts and goals in the management of transfusional iron overload. Am J Hematol 82: 1136-1139.
79. Porter J.B., Davis BA. 2002. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol 15: 329-368.
80. Porter J.B., Huehns ER. 1989. The toxic effects of desferrioxamine. Baillieres Clin Haematol 2: 459-474.
81. Porter J.B., Shah FT. 2010. Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am 24: 1109-1130.
82. Porter J.B., Jaswon MS, Huehns ER, East CA, Hazell JW. 1989. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 73: 403-409.
83. Porter J., Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini M.D., Olivieri N, Piga A, Cunningham MJ, Soulieres D., et al. 2008. Relative response of patients with myelodysplastic syndromes and other transfusiondependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 80: 168-176.
84. Prieto J., Barry M, Sherlock S. 1975. Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology 68: 525-533.
85. Propper R.D., Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG. 1977. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med 297: 418-423.
86. Rebulla P., Modell B. 1991. Transfusion requirements and effects in patients with thalassaemia major. Cooleycare Programme. Lancet 337: 277-280.
87. Roberts D.J., Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ. 2007. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev No. 3: CD004839.
88. Rodda C.P., Reid ED, Johnson S, Doery J, Matthews R, Bowden DK. 1995. Short stature in homozygous β-thalassaemia is due to disproportionate truncal shortening. Clin Endocrinol (Oxf) 42: 587-592.
89. Saxon B., Brittenham G, Nisbet-Brown E, Chait P, Klein N, Muraca M., Olivieri N. 1997. Liver biopsy is safe and provides quantitative guidelines for initiation of chelating therapy in childrenwith thalassemia major. Blood 90: 130a.
90. St. Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey G.P., Olynyk JK, Pootrakul P, Robins E, Lindeman R. 2005. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105: 855-861.
91. Summers M.R., Jacobs A, Tudway D, Perera P, Ricketts C. 1979. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 42: 547-555.
92. Taher A.T., Musallam KM, Cappellini MD, Weatherall DJ. 2011. Optimal management of β thalassaemia intermedia. Br J Haematol 152: 512-523.
93. Taher A.T., Musallam KM, Karimi M, Cappellini MD. 2012. Contemporary approaches to treatment of β-thalassemia intermedia. Blood Rev 26: S24-S27.
94. Tanner M.A., Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. 2008. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 10: 12.
95. Telfer P.T., Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. 2000. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 110: 971-977.
96. Vichinsky E.P., MacKlin EA, Waye JS, Lorey F, Olivieri NF. 2005. Changes in the epidemiology of thalassemia in North America: A new minority disease. Pediatrics 116: e818-e825.
97. Vichinsky E., Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P., Files B, Hassell K, Kelly P, Wilson F, et al. 2007. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136: 501-508.
98. Waldmeier F., Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S., Porter JB. 2010. Pharmacokinetics, metabolism, and disposition of deferasirox in β-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos 38: 808-816.
99. Weatherall DJ. 2010. The inherited diseases of hemoglobin are an emerging global health burden. Blood 115: 4331-4336.
100. Weatherall D., Clegg JB. 2001. The thalassemia syndromes. Blackwell Science, Oxford, England.
101. Worwood M., Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. 1980. Binding of serum ferritin to concanavalin A: Patients with homozygous β thalassaemia and transfusional iron overload. Br J Haematol 46: 409-416.
102. Zurlo M.G., De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A., Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. 1989. Survival and causes of death in thalassaemia major. Lancet 2: 27-30.